A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

June 29, 2021

Study Completion Date

June 29, 2021

Conditions
Advanced Solid Tumor and Lymphoma Malignancies
Interventions
DRUG

TAK-659

TAK-659 tablet

Trial Locations (15)

8035

Hospital Universitari Vall d'Hebron, Barcelona

20132

Ospedale San Raffaele U.O. di Ematologia e Trapianto di midollo osseo, Milan

24127

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

28040

Avda. Reyes Catolicos, 2, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

34232

Florida Cancer Specialists, Sarasota FL, Sarasota

37203

SCRI, Nashville

40138

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna

60611

Northwestern University, Chicago

77030

The Methodist Hospital Research Institute, Houston

78229-3900

University of Texas Health Science Center at San Antonio, San Antonio

00133

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma

WC1E 6AG

University College London Hospitals, London

M20 4BX

The Christie, Manchester

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY